found that GLP-1 receptor agonist use, compared with initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors, was associated with a lower risk of composite MALOs (aHR: 0.84, 95%CI: 0.74-0.94), including specifically lower occurrence of liver decompensation (aHR: 0.83) and all-cause mortality (aHR: 0.84) [56]
Your care team will discuss these possibilities, adjust dosing gradually, and check in regularly to help manage issues such as nausea, vomiting, diarrhea, or other digestive symptoms
FEBS Letters, 211 (2), 169174
En alternative, 1000 mcg peuvent tre administrs quotidiennement SC/IM pendant 2-7 jours, suivis d'un traitement de maintien
A cup of milk has 1.2 mcg
These forms might block the effects of L-carnitine and cause symptoms that resemble L-carnitine deficiency